NiKem Research Receives Approval as a “Crédit d’Impôt Recherche” Certified Company from the French Ministry of Research
News Sep 15, 2008
NiKem Research Srl, an international service provider in the field of Drug Discovery based in Italy, had announced that the French Ministry of Research (FMR) has accepted the company’s request to be included in the list of FMR approved contract research organizations (CROs) carrying out R&D activities for French private companies.
This approval, which is valid for the three year period between 2008 and 2010 and could be renewed afterwards, entitles and will entitle any French private company to claim significant tax credit (“Crédit d’Impôt Recherche”, C.I.R.) for R&D activities executed by NiKem Research on their behalf in the above mentioned time period.
NiKem believes that its C.I.R. certification may now allow a further expansion of business relationships with French companies, and is committed to provide an extremely cost-effective support to any interested French partner.
Giuseppe Giardina, CEO & Managing Director of NiKem, said: "The approval as a C.I.R. certified company by the French Ministry of Research is an important step forward for NiKem. We believe that our already significant business volume with French pharmaceutical and, most importantly, biotech companies will grow: in fact, our high quality standards are now combined with competitive prices and tax credit options. Thus, we expect to at least double our revenues in France in the next three years."
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Drug Combo Prevents Stroke, Shows Promise for ClinicNews
Taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days following a TIAREAD MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018